Orinex5 mg

Orinex is an established, FDA-approved second-generation antihistamine indicated for the relief of symptoms associated with the following conditions:

• Seasonal allergic rhinitis (approved for patients 2 years of age and older) — relieves sneezing, rhinorrhea, itchy/watery eyes, nasal itching, and itching of the palate.
• Perennial allergic rhinitis (approved for patients 6 months of age and older) — relieves nasal congestion, sneezing, and rhinorrhea due to year-round allergen exposure.
• Chronic idiopathic urticaria (approved for patients 6 months of age and older) — reduces pruritus (itching) and the number and size of hives/wheals of unknown cause.

Orinex is not indicated for the treatment of anaphylaxis or acute severe allergic/anaphylactic reactions, and is not an antibiotic or antimicrobial agent.

Desloratadine is available in several dosage forms, each containing Desloratadine as the sole active ingredient:

• Film-coated tablets: Desloratadine 5 mg
• Orally disintegrating tablets (ODT): Desloratadine 2.5 mg and 5 mg
• Syrup/oral solution: Desloratadine 2.5 mg/5 mL
• Pediatric oral drops (in some markets) for infants

Orinex is a long-acting, tricyclic, second-generation (non-sedating) antihistamine. It is the major active metabolite of the first-generation-derived antihistamine loratadine. Orinex acts as a selective and peripherally-restricted antagonist of the histamine H1-receptor, which underlies its efficacy in relieving allergic symptoms with a low propensity for sedation or anticholinergic side effects at recommended doses.

Orinex belongs to the class of second-generation (non-sedating) antihistamines, specifically selective peripheral histamine H1-receptor antagonists.

Mechanism

Desloratadine selectively and competitively antagonizes peripheral histamine H1-receptors. By blocking histamine's action at these receptors, Desloratadine reduces the vasodilation, increased vascular permeability, and sensory nerve stimulation (itching, sneezing) that histamine release produces during allergic reactions.

Pharmacokinetics

• Absorption: Well absorbed orally; peak plasma concentrations of Desloratadine occur approximately 3 hours after dosing.
• Distribution: Highly protein bound (83–87%); does not readily cross the blood-brain barrier at therapeutic doses, accounting for its low sedation profile.
• Metabolism: Extensively metabolized, principally to the active metabolite 3-hydroxydesloratadine, via an as-yet unidentified pathway (not primarily CYP-dependent), though minor CYP2D6/CYP3A4 involvement occurs in some individuals.
• Elimination half-life: Approximately 27 hours, supporting once-daily dosing.
• Excretion: Metabolites are eliminated in urine and feces.

Orinex is taken orally, once daily, at approximately the same time each day, with or without food.

• Tablets: Swallow whole with water.
• Orally disintegrating tablets: Place on the tongue and allow to dissolve; no water is required, though it may be taken with water.
• Syrup: Shake gently if instructed on the label; measure the dose using the calibrated dosing cup/syringe provided, not an ordinary kitchen spoon.

If a dose is missed, it should be taken as soon as remembered unless it is close to the time of the next dose, in which case the missed dose should be skipped. Do not double the dose.

Orinex has a low potential for clinically significant drug interactions. Documented interactions include:

• Ketoconazole, erythromycin, azithromycin (and other CYP3A4 inhibitors): Co-administration increases plasma concentrations of Orinex and its metabolite, but no clinically relevant changes in safety (including QT interval) have been observed in controlled studies.
• Fluoxetine, cimetidine: Similarly increase plasma levels of Orinex without associated clinically significant adverse effects at recommended doses.
• Alcohol and other CNS depressants: Orinex does not potentiate the psychomotor-impairing effects of alcohol in most studies, but concurrent use of alcohol or other CNS depressants (sedatives, opioids) should be approached with caution as individual sensitivity varies.

Orinex is generally well tolerated. Reported adverse effects include:

• Common (adults/adolescents): fatigue, dry mouth, headache, pharyngitis, myalgia, dizziness, nausea, and dyspepsia.
• Common (children): fever, diarrhea, upper respiratory tract infection symptoms, insomnia, and irritability.
• Uncommon: mild somnolence (higher than placebo but generally low), dry mouth.
• Rare but reported: hypersensitivity reactions (rash, pruritus, urticaria, angioedema, anaphylaxis), tachycardia, palpitations, elevated liver enzymes, and hepatitis.

Patients should seek medical attention promptly if signs of a serious allergic reaction (facial/throat swelling, severe rash, difficulty breathing) occur.

Pregnancy

Data on the use of Orinex in human pregnancy are limited. Animal reproduction studies have not shown teratogenic effects at exposures well above the recommended human dose, but this does not guarantee safety in humans. Orinex should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should always be consulted before use. When treatment with an antihistamine is required during pregnancy, second-generation agents such as Orinex are generally preferred over first-generation antihistamines due to their more favorable safety profile.

Lactation

Orinex and its active metabolite pass into human breast milk. A decision should be made, in consultation with a physician, whether to discontinue breastfeeding or discontinue/avoid Orinex, taking into account the benefit of breastfeeding and the mother's clinical need for the medication.

• Renal/hepatic impairment: Clearance of Orinex is reduced in patients with significant renal or hepatic impairment; a lower starting dose (5 mg every other day in adults) is recommended (see Dosage and Administration).
• CNS depressant use/alcohol: Although clinically significant potentiation has not been consistently demonstrated, caution is advised when combining Orinex with alcohol or other CNS depressants, as individual sensitivity to sedation can vary.
• Hypersensitivity: Discontinue immediately if signs of a hypersensitivity reaction occur (see Contraindications and Side Effects).
• General: Do not exceed the recommended dose. Use in children only within the approved age- and weight-based dosing described in Use in Special Populations.

Reported effects of Orinex overdose have included somnolence in adults and, in children, initial CNS excitation followed by somnolence. There is no specific antidote for Orinex overdose. Orinex and its major metabolite are not removed by hemodialysis, and it is not known whether they are removed by peritoneal dialysis.

If an overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Treatment consists of general symptomatic and supportive measures, which should be initiated promptly and maintained as needed under medical supervision. Do not attempt to manage a suspected overdose with home remedies.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Pediatric use: Approved from 6 months of age for perennial allergic rhinitis and chronic idiopathic urticaria (syrup), and from 2 years for seasonal allergic rhinitis. Safety and efficacy of Orinex have not been established in infants below 6 months of age. See Pediatric Uses for full detail.
• Geriatric use: Clinical studies of Orinex have not identified differences in response between elderly and younger patients; dose adjustment based on age alone is not required, though age-related decline in renal/hepatic function should be considered.
• Renal impairment: Reduced dose (5 mg every other day) recommended in adults with significant renal impairment, due to reduced drug clearance.
• Hepatic impairment: Reduced dose (5 mg every other day) recommended in adults with significant hepatic impairment, due to reduced drug clearance.
• Pregnancy and lactation: See Pregnancy and Lactation section.

Duration of Orinex therapy depends on the indication being treated:

• Seasonal allergic rhinitis: Typically used for the duration of seasonal allergen exposure, as needed, under medical guidance.
• Perennial allergic rhinitis and chronic idiopathic urticaria: May be used for longer-term, continuous daily therapy as directed by a physician, with periodic reassessment of ongoing need.

Treatment duration should always follow the prescribing physician's advice rather than a fixed rule.

Desloratadine belongs to the antihistamine drug class, specifically the second-generation (non-sedating), selective peripheral H1-receptor antagonist subclass, and is the major active metabolite of loratadine.

Desloratadine works by selectively binding to and blocking peripheral histamine H1-receptors, preventing histamine (released from mast cells and basophils during allergic reactions) from producing its characteristic effects — vasodilation, increased capillary permeability, mucus secretion, and stimulation of sensory nerve endings that cause itching and sneezing. Because Desloratadine penetrates the central nervous system minimally at therapeutic doses, it produces these anti-allergic effects with a substantially lower risk of sedation compared with first-generation antihistamines.

C

Orinex has established pediatric indications, with dosing and approved age ranges as follows:

• 6 months to 11 years: Approved for perennial allergic rhinitis and chronic idiopathic urticaria, using the age-appropriate syrup dose (see Dosage and Administration).
• 2 years and older: Approved for seasonal allergic rhinitis.
• 6 years and older: Orally disintegrating tablet formulation may be used.
• 12 years and older: Adult tablet dose (5 mg) applies.

Safety and efficacy of Orinex have not been established in infants younger than 6 months of age for any indication; Orinex should not be used in this age group outside specific medical direction.